NCT05907759 2026-03-18
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
National Institutes of Health Clinical Center (CC)
Schrödinger, Inc.
Estrella Immunopharma, Inc.